title: Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.
abstract: In this study we defined the pharmacodynamic parameter that optimizes outcome in deep-seated Candida albicans infections treated with fluconazole. Using a murine model of systemic candidiasis, we conducted single-dose dose-ranging studies with fluconazole to determine the dosage of this drug that resulted in a 50% reduction in fungal densities (50% effective dose [ED50]) in kidneys versus the fungal densities in the kidneys of untreated controls. We found that the ED50 of fluconazole given intraperitoneally was 4.56 mg/kg of body weight/day (95% confidence interval, 3.60 to 5.53 mg/kg/day), and the dose-response relationship was best described by an inhibitory sigmoid maximal effect (Emax) curve. To define the pharmacodynamics of fluconazole, we gave dosages lower than, approximating, and higher than the ED50 of fluconazole (range, 3.5 to 5.5 mg/kg/day, equivalent to the ED16 to the ED75) to various groups of infected animals using three dose-fractionation schedules. For each total dose of fluconazole examined, the dose-fractionation schedules optimized the ratio of the area under the concentration-time curve (AUC) to the MIC (the AUC/MIC ratio), the ratio of the maximum concentration of drug in serum (Cmax) to the MIC, and the time that the drug remained above the MIC for the infecting C. albicans isolate. Similar reductions in fungal densities in kidneys were seen between groups that received the same total dose of fluconazole in one, two, or four equally divided doses. Thus, dose-fractionation studies demonstrated that the pharmacodynamic parameter of fluconazole that best predicted outcome was the AUC/MIC ratio.
authors.affiliation: Department of Medicine, Albany Medical College, New York 12208, USA. arnold_louie_at_amc01-3@ccgateway.amc.edu
authors.forename: A
authors.initials: A
authors.lastname: Louie
authors.forename: G L
authors.initials: GL
authors.lastname: Drusano
authors.forename: P
authors.initials: P
authors.lastname: Banerjee
authors.forename: Q F
authors.initials: QF
authors.lastname: Liu
authors.forename: W
authors.initials: W
authors.lastname: Liu
authors.forename: P
authors.initials: P
authors.lastname: Kaw
authors.forename: M
authors.initials: M
authors.lastname: Shayegani
authors.forename: H
authors.initials: H
authors.lastname: Taber
authors.forename: M H
authors.initials: MH
authors.lastname: Miller
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002177:Candidiasis / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D010865:Pilot Projects
chemical_list: D000935:Antifungal Agents; D015725:Fluconazole